Clinical Trial Search

Primary: Change From Baseline in Mean Seated Trough Cuff Systolic Blood Pressure (SBP) to Week 7 — -28.5; -37.0 mmHg — p=<0.0001

Primary: Change in Mean Systolic Blood Pressure (SBP) — -10.58; -4.65 mmHg — p=<0.0001

Primary: Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8 — -47.5; -36.9; -43.2 mmHg (millimeters of mercury) — p=<0.0001

Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2

Primary: The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal…

Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg

Primary: Percentage of Participants (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped Care, Aliskiren-based Regimen — 86.12 Percentage of…

Primary: Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg — -6.1; -7.1; -8.9 mm Hg — p=0.1187

Primary: Change in Mean Sitting Systolic Blood Pressure After 6 Weeks — 166.8; 168.5; 135.5; 142.5 mmHg

Primary: Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP). — -17.8; -16.5; -14.8; -21.5 mm Hg — p=<0.0001

Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) — -31.37; -27.99; -30.77; -37.92 mmHg

Primary: 24-h, Wake and Sleep Period Systolic and Diastolic Blood Pressure — 143; 133; 136; 87 mmHg

Primary: Change From Baseline in Trough Seated Diastolic Blood Pressure — -6.48; -9.24; -9.33 mmHg — p=<0.0001

Primary: DBP and SBP Change From Baseline in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean — -12.76; -23.82 mmHg

Primary: Change From Baseline in DBP After 8 Weeks of Treatment — -10.19; -12.38 mmHg — p=0.007

Primary: Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) — -5.71; -7.95; -9.35; -10.63 mmHg — p=<0.0001

Primary: Percentage of Patients With Blood Pressure < 140/90 mm Hg — 69.6 Percentage of participants

Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -28.82; -26.22 mmHg

Primary: Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring — -21.4 mm Hg — p=<0.0001

Primary: Blood Pressure — -10.1; -9.1 mm Hg — p=0.50

Primary: Rate of BP Control in Hypertensive Patients — 51.3 Percentage of Participants

Primary: Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life — -3.3; -4.9 mm Hg

Primary: Trough Seated Diastolic Blood Pressure (DBP) Control — 201; 402; 72; 70 patients

Primary: Categorical Classification of Subjects Into Responders vs. Non-responders — 10; 2; 4; 19 Participants

Primary: Adverse Events — 1; 1; 1; 1 participants

Primary: Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. — 18; 20; 22; 7 participants — p=< 0.01

Primary: Compliance With Tarka Treatment, All Participants and by Gender. — 2190; 1141; 1049; 1095 participants

Primary: Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 8 Weeks of Treatment — 168.2; 168.1; 138.8; 139.1 mm Hg

Primary: Composite Adverse Perinatal Outcome — 353; 427; 272; 336 Participants — p=<0.001

Primary: Cognitive Assessment: Trail Making Test Part B — -14; 17; 4 seconds — p=0.008